全文获取类型
收费全文 | 23303篇 |
免费 | 2213篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 334篇 |
儿科学 | 574篇 |
妇产科学 | 469篇 |
基础医学 | 2951篇 |
口腔科学 | 523篇 |
临床医学 | 2485篇 |
内科学 | 4568篇 |
皮肤病学 | 244篇 |
神经病学 | 1927篇 |
特种医学 | 830篇 |
外国民族医学 | 1篇 |
外科学 | 4220篇 |
综合类 | 445篇 |
一般理论 | 30篇 |
预防医学 | 2239篇 |
眼科学 | 564篇 |
药学 | 1535篇 |
中国医学 | 26篇 |
肿瘤学 | 1610篇 |
出版年
2023年 | 180篇 |
2022年 | 253篇 |
2021年 | 757篇 |
2020年 | 421篇 |
2019年 | 700篇 |
2018年 | 790篇 |
2017年 | 560篇 |
2016年 | 567篇 |
2015年 | 630篇 |
2014年 | 843篇 |
2013年 | 1111篇 |
2012年 | 1584篇 |
2011年 | 1521篇 |
2010年 | 901篇 |
2009年 | 752篇 |
2008年 | 1188篇 |
2007年 | 1188篇 |
2006年 | 1070篇 |
2005年 | 1049篇 |
2004年 | 1015篇 |
2003年 | 944篇 |
2002年 | 791篇 |
2001年 | 419篇 |
2000年 | 412篇 |
1999年 | 387篇 |
1998年 | 198篇 |
1997年 | 192篇 |
1996年 | 146篇 |
1995年 | 139篇 |
1994年 | 115篇 |
1993年 | 137篇 |
1992年 | 262篇 |
1991年 | 260篇 |
1990年 | 275篇 |
1989年 | 240篇 |
1988年 | 221篇 |
1987年 | 180篇 |
1986年 | 239篇 |
1985年 | 193篇 |
1984年 | 167篇 |
1983年 | 175篇 |
1982年 | 129篇 |
1980年 | 134篇 |
1979年 | 169篇 |
1978年 | 145篇 |
1977年 | 140篇 |
1976年 | 119篇 |
1975年 | 136篇 |
1974年 | 145篇 |
1973年 | 146篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
5.
6.
7.
8.
9.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
10.
Justin E. Karr Holly K. Rau Jane B. Shofer Rebecca C. Hendrickson Elaine R. Peskind Kathleen F. Pagulayan 《Journal of clinical and experimental neuropsychology》2019,41(7):680-693
Introduction: This study investigated variables associated with subjective decline in executive function among Veterans of Operations Enduring Freedom, Iraqi Freedom, and New Dawn (OEF/OIF/OND) following a history of blast-related mild traumatic brain injury (mTBI).Method: Fifty-six male U.S. Veterans (MAge = 35.3 ± 8.8 years) with a history of blast-related mTBI (6.6 ± 3.2 years post injury) completed a battery of self-report questionnaires and neuropsychological measures. Participants rated current and retrospectively estimated pre-mTBI executive function difficulties on the Frontal Systems Behavior Scale (FrSBe). A difference score (post- minus pre-mTBI ratings) was the dependent variable (?FrSBe). Linear regression models examined variables predicting ?FrSBe, including: pre-injury characteristics (education, premorbid intelligence), injury-related characteristics (number of blast exposures, losses of consciousness), post-injury clinical symptoms (PTSD Checklist–Military version; Pittsburgh Sleep Quality Index), and post-injury neuropsychological performances on executive function measures (Trail Making Test Part B; Controlled Oral Word Association Test; Auditory Consonant Trigrams; Wisconsin Card Sorting Test).Results: While 11% of participants had a clinically elevated pre-injury FrSBe total score, 82% had a clinically elevated post-injury FrSBe total score. Only self-reported PTSD symptom severity independently predicted perceived change in executive function.Conclusions: Many OEF/OIF/OND Veterans with a history of blast-related mTBI experience subjective decline in executive function following injury. Perceived executive function decline was associated with higher PTSD symptom severity, aligning with previous research associating PTSD with cognitive complaints. Results did not support a correspondence between perceived cognitive change and neuropsychological performances. 相似文献